Medigrowth backs National Pain Week 2026 as Gold Sponsor

Medigrowth has been named Gold Sponsor of Chronic Pain Australia’s National Pain Week 2026, a campaign running July 26-31 to spotlight chronic pain and expand access to evidence-based information. The partnership lands as survey data shows growing interest in medicinal cannabis among Australians managing chronic pain.

Why it matters: - Chronic pain affects 5.4 million Australians, making National Pain Week a major awareness campaign for patients, carers and health professionals. - The Medigrowth partnership is aimed at reducing stigma around medicinal cannabis and helping people make safer, better-informed care decisions with qualified clinicians. - Newer National Pain Report data suggest medicinal cannabis is becoming a more common part of pain management in Australia.

What happened: - Medigrowth was announced as Gold Sponsor of National Pain Week 2026, which runs from 26 to 31 July 2026. - Chronic Pain Australia and Medigrowth said the partnership is built around patient-centred research, evidence-based education and awareness activities. - Medigrowth will also be Gold Sponsor of the 2026 National Pain Report. - The sponsorship includes a five-part video series on medicinal cannabis questions patients often hesitate to ask. - Medigrowth also produced a longer interview, “Pain Lives in Women’s Health,” featuring Medigrowth’s Melanie Wentzel and Chronic Pain Australia General Manager Kellie Jade Ellis.

The details: - The five videos are titled: “What’s the Deal with Medicinal Cannabis?”, “What Does Medicinal Cannabis Feel Like?”, “Will People Know I’ve Tried Medicinal Cannabis?”, “Will Medicinal Cannabis Work for Me?” and “Will Medicinal Cannabis Get Me High?” - The partnership is intended to give consumers reliable information and support conversations about treatment options. - The National Pain Survey is the longest-running survey documenting the experiences of Australians living with chronic pain. - Chronic Pain Australia said the past three National Pain Reports show a growing role for medicinal cannabis in chronic pain management. - In 2025, 31% of respondents had accessed medicinal cannabis for pain management, up from 28% in 2024. - A further 27.5% said they would like to or intend to try medicinal cannabis. - That means more than half of respondents either use or are interested in medicinal cannabis as a treatment option. - Over the same period, the barriers people report — cost and driving restrictions — eased slightly year over year. - Medigrowth describes itself as an Australian biotechnology, digital health and clinical research organisation focused on cannabinoid therapeutics and evidence-based healthcare. - Medigrowth said its work includes clinical research, cannabinoid therapeutics for the Australian market and patient support through its digital health platform, Azure Health. - Medigrowth says its research spans women’s health, paediatric populations and chronic pain. - The company pointed to a randomized, double-blind, placebo-controlled clinical trial with Deakin University and Swinburne University studying CBD in children and families living with autism. - Medigrowth also cited the EMPOWER Project, a prospective, HREC-approved real-world evidence study following up to 5,000 patients over four years. - Chronic Pain Australia is a non-profit, non-government organisation and the national voice for 3.6 million Australians living with chronic pain. - Founded in 2001, the group runs National Pain Week, the National Pain Survey, PainLink support services and peer-led Pain Support Groups.

Between the lines: - The sponsorship gives Medigrowth a visible role in a campaign focused on a topic where patient demand appears to be rising faster than public understanding. - The video topics suggest the company is trying to address common concerns about effects, privacy, efficacy and intoxication. - The emphasis on women’s health and endometriosis points to a broader effort to connect medicinal cannabis with underserved pain and health conditions. - The survey data may help normalize medicinal cannabis as one of several pain-management options, while also highlighting access barriers that still shape uptake.

What’s next: - National Pain Week will run from 26 to 31 July 2026, with Chronic Pain Australia and Medigrowth using the campaign to reach more people living with pain. - Chronic Pain Australia will continue pushing for chronic pain to be recognized as a National Health Priority Area. - The 2026 National Pain Report is expected to extend the survey-based picture of how Australians are using and viewing medicinal cannabis.

The bottom line: - Medigrowth is tying its brand to a major chronic pain awareness campaign at a moment when medicinal cannabis is gaining traction among Australian patients, but confusion and access barriers remain.